Up to about 50 years ago, we had a percentage of people who developed senile dementia as part of the aging process, usually occurring after age seventy. Thereafter and inexorably, pre-senile dementia began to increasingly affect individuals as young as fifty. Perhaps in time we will experience the emergence of pre-presenile dementia. The interesting thing about Alzheimer's is the irrefutable link to aluminium and cadmium levels in the brain tissue. The cadmium as a result of passive or side stream tobacco smoke. The aluminium from sources as diverse as aluminium. cooking and drinking vessels to under arm deodorants. Emergent medical studies are looking at the therapeutic role of folic acid as a preventive. Interestingly, homocysteine is also being implicated and of course, this endogenous and toxic amino acid has long been implicated in cardiovascular disease including stroke and, in terms of the neurological system, dementia. And guess what? Folic acid controls homocystein levels. Double
blind controlled trials have shown a derivative of Bovine Colostrum to halt
early dementia A new case of dementia occurs every seven
seconds, according to a report by Alzheimer's Disease International (ADI).
Worldwide, dementia cases are expected to double every 20 years, they say.
Over 81 Million Cases by 2040 Over 24 million people are living with dementia,
and 4.6 million new cases are diagnosed each year. By 2040, over 81 million
people are expected to have the condition. Dementia is spreading across the developing
world at much higher rates than developed countries. While there are 5
million cases in China, for instance, there are 4.8 million in all of
Western Europe and 3.4 million in North America. The report found: A Worldwide Problem Researchers pointed out that policymakers,
clinicians and the public lack awareness as to the gravity of this issue.
They said more support is needed from community-based services and welfare
and health care resources to address what the ADI chairman calls "a ticking
time bomb." The author is researching
and applying the halting and where possible the reversing of brain aging
through
The effect of phosphatidylserine supplementation in Alzheimer's patients has been studied in several large-scale, double-blind, randomized trials. Significant improvements in memory and learning were noted after 12 weeks of supplementation with 300 mg/day. Other studies have shown that phosphatidylserine supplementation may improve motivation, anxiety levels, and apathy scores. A very recent study suggests that phosphatidylserine may be beneficial in children suffering from attention-deficit hyperactivity disorder. There are also indications that it is effective in lowering uric acid levels. The recommended adult dosage for the treatment of
cognitive disorders is 300 mg/day in divided doses. For preventive purposes, 100
mg/day is usually considered sufficient. Soy-derived phosphatidylserine is
considered to be the safest form and it is a good idea to take fish oil capsules
with it as it needs docosahexaenoic acid in order to carry out its functions. No
adverse effects have been reported with dosages of 300 mg/day and there are no
known contraindications or drug interactions. For personal assessment and
recommendations email:functionmed@gmail.com |
|
|